XML 56 R46.htm IDEA: XBRL DOCUMENT v3.25.3
REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 03, 2024
USD ($)
performanceObligation
Dec. 12, 2021
USD ($)
Jul. 31, 2025
USD ($)
Feb. 28, 2025
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2024
USD ($)
Disaggregation of Revenue [Line Items]                      
Total revenue         $ 14,262,000 $ 388,000   $ 243,676,000 $ 508,000    
Accounts receivable         3,492,000     3,492,000     $ 2,742,000
License revenue                      
Disaggregation of Revenue [Line Items]                      
Total revenue         10,000,000 0   205,355,000 0    
Takeda Pharmaceuticals U.S.A., Inc. | License revenue                      
Disaggregation of Revenue [Line Items]                      
Upfront license fee $ 200,000,000.0                    
Reimbursement from limited partnership investment 51,400,000                    
Revenue, remaining performance obligation, variable consideration         34,900,000     34,900,000      
Takeda Pharmaceuticals U.S.A., Inc. | License and Know-How                      
Disaggregation of Revenue [Line Items]                      
Upfront license fee 195,400,000                    
Takeda Pharmaceuticals U.S.A., Inc. | Transition Services                      
Disaggregation of Revenue [Line Items]                      
Upfront license fee $ 56,100,000                    
Hansoh Agreement | Hansoh Shanghai Healthtech Co Ltd                      
Disaggregation of Revenue [Line Items]                      
Total revenue   $ 18,000,000.0         $ 18,000,000.0        
Revenue, remaining performance obligation, development milestones, variable consideration         23,500,000     23,500,000      
Revenue, remaining performance obligation, sales milestones, variable consideration amount         144,000,000.0     $ 144,000,000.0      
Upfront license fee                 3,000,000.0 $ 20,000,000.0  
Withholding taxes from upfront fee                 300,000 $ 2,000,000.0  
License Agreement | Maximum                      
Disaggregation of Revenue [Line Items]                      
Term of the TSA fifteen                    
License Agreement | Minimum                      
Disaggregation of Revenue [Line Items]                      
Term of the TSA six                    
License Agreement | Hansoh Shanghai Healthtech Co Ltd                      
Disaggregation of Revenue [Line Items]                      
Expiration period               10 years      
License Agreement | Takeda Pharmaceuticals U.S.A., Inc.                      
Disaggregation of Revenue [Line Items]                      
Total revenue     $ 10,000,000.0         $ 10,000,000.0      
Expiration period               10 years      
License agreement upfront fee       $ 200,000,000.0              
Potential milestone, development based milestones         80,000,000.0     $ 80,000,000.0      
Potential milestone payments, commercial-based milestones $ 280,000,000.0       280,000,000.0     280,000,000.0      
Potential milestone payments, sales-based milestones $ 740,000,000.0       740,000,000.0     740,000,000.0      
Number of performance obligations | performanceObligation 2                    
Accounts receivable         3,400,000     3,400,000     0
Unearned revenue, current         200,000     200,000     $ 0
Tech Transfer Agreement | Manufacturing Technology Transfer Agreement                      
Disaggregation of Revenue [Line Items]                      
Service revenue         0 3,500   100,000 100,000    
Supply Agreement | Clinical Product Supply Agreement                      
Disaggregation of Revenue [Line Items]                      
Upfront license fee         $ 100,000 $ 400,000   $ 100,000 $ 400,000